The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering leader in gene-editing technology, leveraging its proprietary gene sequencing platform to develop precise DNA modification therapies for ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science Foundation’s Faculty Early Career Development Program (CAREER) for ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR-guided endonucleases were an obvious route, but for RNA, the options were few and imperfect. Cas13 proved useful for RNA knockdown, but it caused collateral damage to non-target RNA. Although ...

Financial disclosures released ahead of confirmation hearings for Robert F. Kennedy Jr., President Trump’s nominee to lead the health ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...